» Articles » PMID: 32296140

Global Burden of Irritable Bowel Syndrome: Trends, Predictions and Risk Factors

Overview
Specialty Gastroenterology
Date 2020 Apr 17
PMID 32296140
Citations 182
Authors
Affiliations
Soon will be listed here.
Abstract

Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction worldwide, defined according to patterns of gastrointestinal symptoms as described by the Rome diagnostic criteria. However, these criteria, developed with reference to research conducted largely in Western populations, might be limited in their applicability to other countries and cultures. Epidemiological data show a wide variation in the prevalence of IBS globally and more rigorous studies are needed to accurately determine any differences that might exist between countries as well as the potential explanations. The effects of IBS on the individual, in terms of their quality of life, and on health-care delivery and society, in terms of economic costs, are considerable. Although the magnitude of these effects seems to be comparable between nations, their precise nature can vary based on the existence of societal and cultural differences. The pathophysiology of IBS is complex and incompletely understood; genetics, diet and the gut microbiome are all recognized risk factors, but the part they play might be influenced by geography and culture, and hence their relative importance might vary between countries. This Review aims to provide an overview of the burden of IBS in a global context, to discuss future implications for the care of people with IBS worldwide, and to identify key areas for further research.

Citing Articles

Characterization of post-inflammatory irritable bowel syndrome animal model following acute colitis recovery.

Jeong E, Jung H, Choi E, Yun K, Lee A, Kim Y Sci Rep. 2025; 15(1):8512.

PMID: 40075091 PMC: 11904205. DOI: 10.1038/s41598-025-88981-7.


Irritable bowel syndrome remains a complex disorder of gut-brain interaction: Too many actors on stage.

Pellegrino R, Gravina A World J Gastroenterol. 2025; 31(8):101357.

PMID: 40062329 PMC: 11886521. DOI: 10.3748/wjg.v31.i8.101357.


Sex-dependent alterations of colonic epithelial permeability: relevance to irritable bowel syndrome.

Larauche M, Mahurkar-Joshi S, Biraud M, Ju T, Mayer E, Chang L Front Physiol. 2025; 16:1509935.

PMID: 40061455 PMC: 11885305. DOI: 10.3389/fphys.2025.1509935.


Lacidophilin tablets relieve irritable bowel syndrome in rats by regulating gut microbiota dysbiosis and intestinal inflammation.

Fan H, Zhan Y, Cheng X, Tan M, Li Y, Xiong Y Sci Rep. 2025; 15(1):8151.

PMID: 40059226 PMC: 11891319. DOI: 10.1038/s41598-025-91883-3.


Quality of life, functional impairment and healthcare experiences of patients with irritable bowel syndrome in Norway: an online survey.

El-Salhy M, Johansson M, Klevstul M, Hatlebakk J BMC Gastroenterol. 2025; 25(1):143.

PMID: 40050743 PMC: 11883911. DOI: 10.1186/s12876-025-03685-6.


References
1.
Lovell R, Ford A . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7):712-721.e4. DOI: 10.1016/j.cgh.2012.02.029. View

2.
Canavan C, West J, Card T . Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9):1023-34. DOI: 10.1111/apt.12938. View

3.
Gwee K . Irritable bowel syndrome in developing countries--a disorder of civilization or colonization?. Neurogastroenterol Motil. 2005; 17(3):317-24. DOI: 10.1111/j.1365-2982.2005.00627.x. View

4.
Gwee K, Wee S, Wong M, Png D . The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an asian urban community. Am J Gastroenterol. 2004; 99(5):924-31. DOI: 10.1111/j.1572-0241.2004.04161.x. View

5.
Xiong L, Chen M, Chen H, Xu A, Wang W, Hu P . A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmacol Ther. 2004; 19(11):1217-24. DOI: 10.1111/j.1365-2036.2004.01939.x. View